Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Authors : Nuciforo P, Townend J, Piccart-Gebhart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S Year : 2023 Journal : Eur J Cancer
How I treat endocrine-dependent metastatic breast cancer.
Authors : Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A Year : 2023 Journal : ESMO Open
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
Authors : Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV Year : 2022 Journal : Cancer Med
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G Year : 2022 Journal : NPJ Breast Cancer
MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunitie
Authors : Awada A, Gombos A Year : 2022 Journal : TBCR